Calyxo Secures $40M in Series F Funding Led by Ally Bridge Group

The round also saw participation from Questa Capital, Avidity Partners, and CRG.

The company plans to use the funds to grow its commercial operations, support clinical studies to show long-term outcomes and healthcare impact, and continue developing new solutions for kidney stone care.

The funding comes after a major milestone of treating 40,000 patients with the CVAC System. Its growing use shows that more doctors believe complete stone removal leads to better patient outcomes.

The CVAC System continuously removes stone fragments, helping achieve more complete stone clearance. Studies show it leaves fewer leftover stones, improves procedure efficiency, and reduces follow-up healthcare use and costs. These results highlight that removing more of the stone is key to better outcomes and is becoming an important measure of success in kidney stone treatment.

Read More:Sygaldry Raises $105M in Series A Funding

“Ally Bridge Group is pleased to lead this funding to support Calyxo’s growth,” said Kevin Reilly, Managing Director and Head of Medtech at Ally Bridge Group. “The company is meeting an important need in kidney stone treatment with a unique approach backed by strong clinical results and growing use by doctors. We are excited to work with the Calyxo team as they continue to grow.”

“This funding is an important milestone for Calyxo,” said Joe Catanese, CEO of Calyxo. “More than 40,000 patients have been treated with the CVAC System, and both real-world use and clinical data show it is becoming a key part of standard kidney stone care. This funding will help us improve our technology and expand research to enhance patient outcomes further.”

About Calyxo, Inc.

Founded in 2016, by Jee Shin, Calyxo, Inc. is a medical device company focused on improving kidney stone care. It develops innovative solutions that help doctors treat patients more safely, effectively, and efficiently, thereby improving outcomes.

About Kidney Stones

According to the American Urological Association, about 10% of people in the U.S. will experience kidney stones at some point. It is a painful condition that can also lead to high healthcare costs, with estimates reaching $4.1 billion annually by 2030.

Read More:Spiral Therapeutics Raises $27M in Series B Funding